Redx Pharma PLC - Macclesfield-based cancer treatment firm - Narrows pretax loss to GBP4.0 million in six months to March 31 from GBP4.1 million loss a year ago. Reports revenue of GBP1.2 million, versus none in first six months of prior year. Plans to raise USD30 million through issue of USD29 million convertible loan notes and a GBP812,000 share subscription from investment fund Sofinnova Crossover I SLP.
Current stock price: 22.50 pence
Year-to-date change: up more than double from 8.00p
By Eric Cunha; email@example.com
Copyright 2020 Alliance News Limited. All Rights Reserved.